This session highlights the intersection of genomic and epigenomic changes in cancer. It explores how mutations, copy number variations, and epigenetic modifications, such as DNA methylation and histone modifications, contribute to tumorigenesis. At the Cancer Research and Development Conference 2025, experts will discuss how next-generation sequencing and epigenetic profiling advances are enabling more precise cancer diagnostics and targeted therapies. The session will also address the role of cancer genome atlas data in identifying key biomarkers for personalized treatment strategies.